With the approval of disease-modifying agents aducanumab and lecanemab in the US, establishing a method to diagnose Alzheimer’s disease (AD) in its earliest stages using fluid biomarkers has become a priority. Henrik Schinke, PhD, Roche Diagnostics Europe, Penzberg, Germany, presents some of the remaining challenges in bringing fluid biomarkers into routine clinical practice. Firstly, the current use of fluid biomarkers is largely restricted to research settings, which means that healthcare systems are generally not prepared to deal with a high demand of tests that utilize fluid biomarkers. In line with this, clinical guidelines would need to be updated to include these types of tests. Finally, particular attention should be given to developing robust clinical protocols that could be used regularly and reliably in healthcare settings. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
